Stockscreener 앱 받기
7.13
0.56%
-0.04
시간 외 거래:
7.13
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media
Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media
Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media
TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Liquidity Mapping Around (TRDA) Price Events - Stock Traders Daily
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - tradingview.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics (NASDAQ: TRDA) insider sells near $7 a share - Stock Titan
Entrada Therapeutics (TRDA) backer MPM funds sell 86,914 shares around $7 - Stock Titan
We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully - Sahm
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com - Investing.com Australia
Entrada Therapeutics (TRDA) 10% owner sells shares outside a 10b5-1 plan - Stock Titan
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX) - The Globe and Mail
Entrada (TRDA) Results Breakdown: Reported EPS Tops Expectations at the Close; Investor Response: Shares Move 2.31% Lower at the CloseShare Repurchase Impact - vinanet.vn
Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day; Share Move: Shares Move Higher 7.02%Analyst Earnings Estimate - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock - MarketBeat
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock - MarketBeat
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan
Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary - TradingView
Entrada Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times
Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M - TradingView
Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline - Stock Titan
Entrada Therapeutics director Kush Parmar sells $807,027 in shares By Investing.com - Investing.com India
5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com - Investing.com India
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
5am Ventures V sells $807,027 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics director Kush Parmar sells $807,027 in shares - Investing.com
Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - marketbeat.com
0.86%
0.31%
자본화:
|
볼륨(24시간):